Alexavi will be managing an Early Access to Treatment program on behalf of Double Bond to raise awareness of the treatment's availability to physicians and patients across the globe.

Glioblastoma, the most common and aggressive malignant form of all primary brain tumours, affects glial cells and accounts for 52% of all brain tissue tumour cases and 20% of all tumours inside the skull. Approximately 250,000 patients with Glioblastomas are identified globally each year.

The current standard of care is surgery followed by radiation and chemotherapy.  Double Bond's Temodex® is a chemotherapy drug administered directly at the site of the tumour following surgical removal, in the form of a gel, thus ensuring that the therapeutic effect is felt precisely where it is needed. Temozolomide is a prodrug which destroys the tumour's DNA and triggers the death of tumour cells.

Double Bond Pharmaceutical acquired Orphan Drug Designation for Temodex® (Temozolomide gel) from the European Medicines Agency in 2016.  Whilst developing their own form of this product further (currently known as SI-053), they are making this available to physicians across the globe.

About Alexavi Ltd: www.alexavi.com/ Alexavi is a global development and commercialisation services supplier to the pharmaceutical, biotech, medical device and medicinal products industry, founded in 2021 with the aim of assisting companies of varying sizes to meet their development and commercialisation goals in a compliant, cost and time effective manner. Alexavi seeks to change the current paradigm of service provision in this sector with an emphasis on getting new treatments to patients faster.

About Early Access to Treatment program: www.alexavi.com/our-programs

This disclosure contains information that DBP is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 04-11-2021 08:30 CET.